Santen Pharmaceutical Co., Ltd.
SNPHY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.61B
Close$
$15.89
41.5% upside
Current Fair Value
41.5% upsideUndervalued by 41.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.61 Billion |
|---|---|
| Enterprise Value | $-43,300,602,993.00 |
| Annual dividend | $0.23 |
| Dividend yield | 2.31% |
| Earnings per Share | $121.43 |
| Beta | 0.24 |
| Outstanding Shares | 321,344,079 |
Return
| Return on Equity | 13.03% |
|---|---|
| Return on Assets | 9.41% |
| Return on Invested Capital | 13.93% |
Valuation & Multiples
| P/E Ratio | 14.56 |
|---|---|
| PEG | 67.71 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 1.74 |
| Enterprise Value to EBIT | 10.92 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Institutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%0% |
|---|---|
| Total Invested | $403▲ 21.02% |
| Investors Holding | 10% |
About Santen Pharmaceutical Co., Ltd.
3,968 employees
CEO: Takeshi Ito
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addr...